On the other hand, a host of biopharma firms face near-constant threats of collapse, given that most of these companies lack sufficient revenue to sustain operations for long unless a breakthrough occurs.
Investors outside the space may wonder how to balance their own risk tolerance with the risk/reward profile of many biopharma companies. Although it's not a guarantee of success, one approach involves deferring to Wall Street analysts who are experts in the healthcare sector.
